[{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yuhan\u2019s Lung Cancer Treatment Lazertinib Wins Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"J Ints Bio","pharmaFlowCategory":"D","amount":"$325 million","upfrontCash":"$1.9 million","newsHeadline":"Yuhan Corporation and J INTS BIO Inked a Licensing Agreement for A New Drug Candidate Targeting HER2 NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Yuhan Corporation
The license agreement is for JIN-A04, an oral Tyrosine Kinase Inhibitor (TKI) targeting non-small cell lung cancer carrying HER2 mutations. There is currently no oral drug approved to date.
The Ministry of Food and Drug Safety announced its approval for the third-generation non-small cell lung cancer treatment, Leclaza. Leclaza is a swallowable tablet that can be taken at a fixed time every day, regardless of meals.